131 related articles for article (PubMed ID: 14670552)
1. Development of weekly high-dose calcitriol based therapy for prostate cancer.
Beer TM
Urol Oncol; 2003; 21(5):399-405. PubMed ID: 14670552
[TBL] [Abstract][Full Text] [Related]
2. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Beer TM; Hough KM; Garzotto M; Lowe BA; Henner WD
Semin Oncol; 2001 Aug; 28(4 Suppl 15):49-55. PubMed ID: 11685729
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol in cancer treatment: from the lab to the clinic.
Beer TM; Myrthue A
Mol Cancer Ther; 2004 Mar; 3(3):373-81. PubMed ID: 15026558
[TBL] [Abstract][Full Text] [Related]
4. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
Beer TM
BJU Int; 2005 Sep; 96(4):508-13. PubMed ID: 16104901
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.
Beer TM; Myrthue A; Eilers KM
World J Urol; 2005 Feb; 23(1):28-32. PubMed ID: 15668801
[TBL] [Abstract][Full Text] [Related]
6. Calcitriol in the treatment of prostate cancer.
Beer TM; Myrthue A
Anticancer Res; 2006; 26(4A):2647-51. PubMed ID: 16886675
[TBL] [Abstract][Full Text] [Related]
7. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Beer TM; Eilers KM; Garzotto M; Egorin MJ; Lowe BA; Henner WD
J Clin Oncol; 2003 Jan; 21(1):123-8. PubMed ID: 12506180
[TBL] [Abstract][Full Text] [Related]
8. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Redfern CH; Fehrenbacher L; Saleh MN; Waterhouse DM; Carducci MA; Vicario D; Dreicer R; Higano CS; Ahmann FR; Chi KN; Henner WD; Arroyo A; Clow FW;
J Clin Oncol; 2007 Feb; 25(6):669-74. PubMed ID: 17308271
[TBL] [Abstract][Full Text] [Related]
9. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Chi KN; Young J; Henner WD;
Cancer; 2008 Jan; 112(2):326-30. PubMed ID: 17960793
[TBL] [Abstract][Full Text] [Related]
10. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D-related therapies in prostate cancer.
Johnson CS; Hershberger PA; Trump DL
Cancer Metastasis Rev; 2002; 21(2):147-58. PubMed ID: 12465754
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
[TBL] [Abstract][Full Text] [Related]
14. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
Beer TM; Lemmon D; Lowe BA; Henner WD
Cancer; 2003 Mar; 97(5):1217-24. PubMed ID: 12599228
[TBL] [Abstract][Full Text] [Related]
15. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; De Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
BJU Int; 2007 Oct; 100(4):775-9. PubMed ID: 17535276
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
[TBL] [Abstract][Full Text] [Related]
18. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation.
Beer TM; Munar M; Henner WD
Cancer; 2001 Jun; 91(12):2431-9. PubMed ID: 11413535
[TBL] [Abstract][Full Text] [Related]
19. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
